Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)

被引：0
|
作者：
Liao, M. [1 ]
Yang, Y. [2 ,5 ]
Jiang, H. [3 ]
Huang, J. [1 ]
Liu, C. [4 ]
Yang, Y. [2 ,5 ]
Xie, K. [6 ]
Luo, X. [7 ]
Zhou, J. [1 ]
Wang, X. [8 ]
Wu, H.
Zeng, Y. [9 ]
Li, Q. [5 ]
机构：
[1] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Liver Transplant Ctr, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China
[8] Sichuan Univ, West China Hosp, Div Abdominal Tumor Multimodal Treatment, Dept Radiat Oncol, Chengdu, Peoples R China
[9] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
中国博士后科学基金;
关键词：
D O I：
10.1016/j.annonc.2024.08.1026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
966P
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study
    Liu, Ming
    Wang, Kun
    Bao, Quan
    Wang, Hongwei
    Jin, Kemin
    Liu, Wei
    Luo, Jia
    Xu, Nong
    Zhang, Tao
    Xia, Yongxiang
    Shao, Guoliang
    Liu, Baorui
    Shen, Jie
    Chen, Haonan
    Long, Sixiang
    Chen, Yuling
    Zhao, Li
    Wang, Hongli
    Xing, Baocai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study-The CISLD-12 study.
    Liang, Tingbo
    Chen, Yiwen
    Huang, Xin
    Hu, Wendi
    Li, Xiang
    Sun, Junhui
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Bai, Xueli
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 558 - 558
  • [23] A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage
    Zhou, Jian
    Fan, Jia
    Gu, Fang-Ming
    Li, Tao
    Bai, Dou-Sheng
    Sun, Hui-Chuan
    Wang, Zheng
    Qiu, Shuang-Jian
    Ye, Qing-Hai
    Shi, Ying-Hong
    Gao, Qiang
    Wang, Xiao-Ying
    Yang, Xin-Rong
    Shi, Guo-Ming
    Peng, Yuan-Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial
    Chen, Zhiyu
    Zhang, Leida
    Zhang, Hui
    Gong, Yi
    Feng, Kai
    Ma, Kuansheng
    Bi, Huaqiang
    Xia, Feng
    Dai, Haisu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
    Kudo, Masatoshi
    Finn, Richard S.
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Kumada, Hiromitsu
    Wang, Anran
    Mody, Kalgi
    Dubrovsky, Leonid
    Siegel, Abby B.
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 482 - 482
  • [26] Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.
    Yang, Hang
    Zhang, Guoqing
    Li, Xiangnan
    Jiao, Jia
    Guo, Yanan
    Zhang, Yan
    Hou, Zhichao
    Huang, Qi
    Zhao, Jia
    Li, Jindong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 360 - 360
  • [27] Preoperative administration of camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): study protocol of a single-arm, open-label, phase II study
    Yang, Hang
    Guo, Yanan
    Zhao, Jia
    Zhang, Yan
    Jiao, Jia
    Mu, Teng
    Hou, Zhichao
    Huang, Qi
    Zhang, Guoqing
    Li, Xiangnan
    Li, Jindong
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4702 - 4710
  • [28] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Yi, Fengming
    Jiang, Weiming
    Feng, Long
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 500 - 500
  • [29] Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.
    Zeng, Hui
    Shao, Guoliang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 581 - 581
  • [30] Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
    Chen, Jinzhang
    Zang, Mengya
    Pang, Huajin
    Li, Chuanjiang
    Zhao, Jianbo
    Guo, Yabing
    Hou, Jinlin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345